Table 5.
Biologics and fusion rates
| Study | Biologics | Fusion rates/time/imaging |
|---|---|---|
| Anand et al., 2008 [5] | rhBMP2, Grafton Putty DBM | NR |
| Benglis et al., 2008 [9] | rhBMP2 | 100% 6 months, XR or CT |
| Anand et al., 2010 [6] | rhBMP2, Grafton Putty DBM | 100 % 1 year, XR or CT |
| Dakwar et al., 2010 [13] | rhBMP2 | 80% 6 months, XR or CT |
| Tormenti et al., 2010 [39] |
XLIF: AF versus DBM TLIF: IC versus BMP |
NR |
| Wang and Mummaneni, 2010 [43] | BMP ± facet versus vertebral body versus iliac crest versus rib autograft versus allograft | 100% interbody levels, 71.4% posterolateral levels without interbody fusion, fine-cut CT |
| Isaacs et al., 2010 [25] | Yes, not specified | NR |
| Marchi et al., 2012 [30] | NR | NR |
| Wang, 2012 [42] | NR | NR |
| Deukmedjian et al., 2012 [16] | Allograft | NR |
| Deukmedjian et al., 2013 [15] | NR | 100% 1 year, CT |
| Anand et al., 2013 [4] | XLIF: rhBMP2, Grafton Putty DBM | 94.4% 2 years, NR |
| AxialLIF: rhBMP2, local autograft, DBM | ||
| Caputo et al., 2012 [10] | Allograft cellular bone matrix | XLIF: 88.2% 1 year, CT; XLIF + ALIF: 90.9% 1 year, CT |
AF = Actifuse bone graft; DMB = demineralized bone matrix; IC = autologous Iliac crest; BMP = bone morphogenic protein; XLIF = extreme lateral interbody fusion; TLIF = transforaminal lumbar interbody fusion; XR = dynamic radiograph; NR = not reported.